tadalafil has been researched along with panobinostat in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (panobinostat) | Trials (panobinostat) | Recent Studies (post-2010) (panobinostat) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 678 | 95 | 593 |
| Protein | Taxonomy | tadalafil (IC50) | panobinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 8 | Schistosoma mansoni | 0.45 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.2031 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.005 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.0033 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.3792 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.181 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.9434 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2527 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.007 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.8396 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2307 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5825 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.3424 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0025 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W | 1 |
1 other study(ies) available for tadalafil and panobinostat
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Topics: Acetylation; Alzheimer Disease; Animals; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors | 2016 |